Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment

Type 2 diabetes (T2D) is a complex and progressive disease requiring polypharmacy to manage hyperglycaemia and cardiovascular risk factors. However, most patients do not achieve combined treatment goals. To address this therapeutic gap, we have developed MEDI4166, a novel glucagon-like peptide-1 (GL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Chodorge, Matthieu, Celeste, Anthony J., Grimsby, Joseph, Konkar, Anish, Davidsson, Pia, Fairman, David, Jenkinson, Lesley, Naylor, Jacqueline, White, Nicholas, Seaman, Jonathan C., Dickson, Karen, Kemp, Benjamin, Spooner, Jennifer, Rossy, Emmanuel, Hornigold, David C., Trevaskis, James L., Bond, Nicholas J., London, Timothy B., Buchanan, Andrew, Vaughan, Tristan, Rondinone, Cristina M., Osbourn, Jane K.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6277417/
https://ncbi.nlm.nih.gov/pubmed/30510163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-35869-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados